Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis JOURNAL OF RHEUMATOLOGY Peterfy, C., DiCarlo, J., Emery, P., Genovese, M. C., Keystone, E. C., Taylor, P. C., Schlichting, D. E., Beattie, S. D., Luchi, M., Macias, W. 2019; 46 (8): 887–95
View details for DOI 10.3899/jrheum.171469
View details for Web of Science ID 000478078100004